China Anti-vascular Endothelial Growth Factor Therapeutics Market Size & Outlook
China anti-vascular endothelial growth factor therapeutics market, 2018-2030 (US$M)
Related Markets
China anti-vascular endothelial growth factor therapeutics market highlights
- The China anti-vascular endothelial growth factor therapeutics market generated a revenue of USD 136.6 million in 2024 and is expected to reach USD 95.2 million by 2030.
- The China market is expected to grow at a CAGR of -6.3% from 2025 to 2030.
- In terms of segment, eylea was the largest revenue generating product in 2024.
- Vabysmo is the most lucrative product segment registering the fastest growth during the forecast period.
Anti-vascular endothelial growth factor therapeutics market data book summary
| Market revenue in 2024 | USD 136.6 million |
| Market revenue in 2030 | USD 95.2 million |
| Growth rate | -6.3% (CAGR from 2025 to 2030) |
| Largest segment | Eylea |
| Fastest growing segment | Vabysmo |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
| Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
Other key industry trends
- In terms of revenue, China accounted for 0.9% of the global anti-vascular endothelial growth factor therapeutics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan anti-vascular endothelial growth factor therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 95.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anti-Vascular Endothelial Growth Factor Therapeutics Market Scope
Anti-Vascular Endothelial Growth Factor Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China anti-vascular endothelial growth factor therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 56.66% in 2024. Horizon Databook has segmented the China anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
China’s anti-VEGF therapeutics market is anticipated to witness significant growth over the forecast period, owing to a strong product pipeline and multiple product launches. In December 2020, Kanghong Pharmaceutical announced the completion of primary endpoint of phase 3 clinical trial on Conbercept for the indication of wet AMD.
The product was approved by NMPA in 2014 and is expected to launch globally by 2023. The penetration of biosimilars can enhance the bargaining power of buyers, however, negatively impacting the overall market growth. In June 2020, Innovent received NMPA’s approval for the launch of BYVASDA (bevacizumab biosimilar) in China. This product is used off-label for the indication of wet AMD.
Reasons to subscribe to China anti-vascular endothelial growth factor therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China anti-vascular endothelial growth factor therapeutics market databook
-
Our clientele includes a mix of anti-vascular endothelial growth factor therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into China anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China anti-vascular endothelial growth factor therapeutics market size, by product, 2018-2030 (US$M)
China Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
